Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 1997

View Archived Issues

Synthetic retinoids with anticoagulant effects

SDZ-MRL-953 prevents sepsis in cancer patients

Preclinical profile of Ono-1101 published

SciClone issued European patent for use of thymosin alpha 1 for hepatitis C

Matrix discontinues U.S. development of AccuSite

Biomira reports phase II results for cancer vaccine

Preclinical studies show broad antiseizure properties of ganaxolone

Oncologic Drugs Advisory Committee meets this week

LG Chemical licenses thrombin inhibitor to Warner-Lambert

NC-1800 now in phase II development

Chugai accelerates R&D outside Japan

Pharmacological characterization of BIBU-52

Kirin's TPO enters phase II in several Asian countries

Kyowa Hakko antiparkinsonian enters phase II trials

Amphetamines may provide long-term benefit in patients with ADHD

MIT licenses drug discovery technology to Dyax

Benefits of magnesium sulfate investigated in patients with unstable angina

Cytel and Searle to collaborate on cancer therapies

Myocardial and cerebral vasodilating effects of BMS-180448 in animals

Molecumetics and Teijin begin oral thrombin inhibitor collaboration

Potent GH secretagogues synthesized at Merck & Co.

Gene Logic and Japan Tobacco enter genomic alliance

Novel antibacterial agents from R.W. Johnson

Novartis evaluates SDZ-267-489 and analogues for increasing HDL cholesterol

Cardiovascular effects of SB-209509 and sumatriptan compared in dogs

Hormone therapy vs. simvastatin for hypercholesterolemia in postmenopausal women

Novel neuroprotective agent developed at Takeda

Mitsubishi describes synthesis and activity of MKC-242

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...